Serum Institute of India CEO Adar Poonawalla, on May 8, suggested Elon Musk to invest in India for Tesla manufacturing. Tagging the Tesla boss in the tweet, he wrote "do look at investing some of that capital in INDIA for high-quality large-scale manufacturing of @Tesla cars. I assure you this will be the best investment you'll ever make (sic).” Nitik Gadkari had earlier said that Musk was welcome to India.
Courtesy: Hindustan Times
The Drug Controller General of India (DCGI) approved the Serum Institute of India's (SII) Covovax for children between 12-year to 17-year-old. However, the Emergency Use Authorisation came with certain conditions. Previously Covovax was given approval for restricted usage amongst adult. Furthermore, the SII conducted clinical trials on approximately 2,000 children, which shows the efficiency for children against COVID-19 virus, as only… read-more
Courtesy: News 18
Pune based Serum Institute of India (SII) on February 4, wrote to Union Health Minister Mansukh Mandaviya, to reduce booster dose gap from nine months to three. The SII Director and Government Affairs official Prakash Kumar Singh, further asked to allow Covishield precaution dose for all above 18-years-old. The letter was written on the lines of revised guidelines, allowing booster dose for people on election duties with three months gap. … read-more
Courtesy: One India
The two COVID-19 vaccines, Covishield and Covaxin will soon get the regular market approval with capped prices. According to the Drug Controller General of India, the SII and Bharat Biotech urged the DGCI to grant regular market approval for adult population with certain conditions. If approved, vaccines will be available at Rs 275 plus Rs 150 additional charges. Notably, Covaxin and Covishield are available at Rs 1,200 and 780, respectively… read-more
Courtesy: Zee News
Adar Poonwalla, CEO of the Serum Institute of India (SII) applied for full market authorisation of its COVID-19 vaccine, Covishield, on December 31. "Supplies of Covishield vaccine in India, exceeded 1.25 billion doses. The Government of India now has enough data to allow full market authorisation," tweeted SII CEO. The application has been submitted to the Union Government and MoHFW. Besides, SII's Covishield also export vaccine doses to… read-more
Courtesy: News 18
India has approved the shipment of 20 million doses of the Novavax (NVAX.O) COVID-19 vaccine developed by the Serum Institute of India (SII) to Indonesia, according to reports. Further, the government has also decided to allow 10 million doses of Covishield, also manufactured by SII, to be exported on the global vaccine-sharing program. As per sources, the government has no plans to place an order for Merck & Co.'s COVID-19 pill.
As per reports, India's drug regulator has allowed Covishield's maker Serum Institute of India (SII) to enroll children aged between seven to 11 years for its COVID-19 vaccine trial. The Central Drugs Standard Control Organisation's (CDSCO) subject expert panel made the recommendation after "detailed deliberation". SII is already conducting a trial of its COVID-19 vaccine in the 12-17 age group and has presented safety data for an initial 100… read-more
Union Health Ministry data on August 18 stated India has registered 35,178 new coronavirus cases totaling the tally up to 3,22,85,857. The death toll has reached 4,32,519 as 440 new deaths have occurred. Meanwhile, the national recovery rate has improved to 97.52% since March 2020. SII chairman Cyrus Poonawalla requested, "Who have completed the second dose, it is my request to take a booster dose after six months."
Courtesy: Money Control
The Chairman of the Serum Institute of India (SII) Cyrus Poonawalla on August 13 criticized the Modi government's decision to ban the vaccine exports as a ''very bad move''. Poonawalla also said, ''My Son asked me not to open my mouth. But It's my view that exports ought to be opened.'' He said those who paid ''crores in advance'' for vaccines were blaming the company for denying the supply.
Courtesy: The Free Press Journal
The Covidshield vaccine produced by the Serum Institute of India (SII) offers 93% protection against Covid-19 and a 98% reduced mortality rate, the government said referring to a study done by the Armed Forces Medical College (AFMC). NITI Aayog member Dr. V K Paul said that the study was conducted on 15 lakh doctors and frontline workers in AFMC who were administered with Covishield.